SPOTLIGHT: Advaxis vaccine demonstrates potential

Advaxis says it is developing a vaccine that could be effective in combating cervical cancer. The company says that its vaccine has proven safe in women with advanced cervical cancer in a small trial of seven stable patients. Three of the women demonstrated a reduction of tumor mass following therapy. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.